睿知中国医院研究地图
候选清单

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由首都医科大学附属北京友谊医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07353684,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.

    入选标准第 2 条

  3. Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.

    排除标准第 7 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    入选标准第 6 条

  5. Absolute neutrophil count ≥ 1.5 × 10⁹/L.

    入选标准第 9 条

    Hemoglobin ≥ 90 g/L (9.0 g/dL).

    入选标准第 10 条

    Platelet count ≥ 100 × 10⁹/L.

    入选标准第 11 条

  6. Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose

    入选标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07353684,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-75 years at the time of enrollment, with an estimated life expectancy of ≥ 3 months.
  2. Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.
  3. Unresectable locally advanced gastric or gastroesophageal junction adenocarcinoma (Stage III or IV), as determined by the investigator based on CT, MRI, and/or PET-CT.
  4. Disease with conversion (translational) therapeutic potential, as assessed by the investigator.
  5. No prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic anticancer therapies.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  7. Adequate hematologic function within 14 days prior to enrollment:
  8. White blood cell count ≥ 3.5 × 10⁹/L.
  9. Absolute neutrophil count ≥ 1.5 × 10⁹/L.
  10. Hemoglobin ≥ 90 g/L (9.0 g/dL).
  11. Platelet count ≥ 100 × 10⁹/L.
  12. Adequate hepatic function within 14 days prior to enrollment:Total bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2.5 × ULN in patients without liver metastases;ALT and AST ≤ 5 × ULN in patients with liver metastases;Adequate renal function:Serum creatinine ≤ 1.5 × ULN;Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 12 weeks after the last dose.
  13. Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose
  14. Ability to understand and willingness to sign a written informed consent form
  15. Expected to comply with study procedures and follow-up requirements

排除标准:Exclusion Criteria:

  1. HER2-positive gastric or gastroesophageal junction adenocarcinoma.
  2. Conditions that may significantly affect oral drug absorption, including inability to swallow, persistent nausea or vomiting, chronic diarrhea, or intestinal obstruction.
  3. Known hypersensitivity or allergy to adebrelimab, apatinib, oxaliplatin, S-1 (tegafur/gimeracil/oteracil), or any of their excipients.
  4. History of severe allergic reactions to monoclonal antibodies.
  5. Active autoimmune disease or autoimmune disorders requiring systemic treatment.
  6. Congenital or acquired immunodeficiency.
  7. Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.
  8. Administration of live attenuated vaccines within 4 weeks prior to the first dose or planned during the study period.
  9. Severe infection within 4 weeks prior to initiation of study treatment.
  10. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  11. Evidence of interstitial lung disease, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severely impaired pulmonary function.
  12. Uncontrolled hypertension despite at least 3 months of antihypertensive treatment.
  13. Uncontrolled clinically significant cardiovascular disease.
  14. High risk of severe bleeding, as judged by the investigator.
  15. Peripheral neuropathy of Grade > 2 according to CTCAE.
  16. Participation in another interventional clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
  17. Any condition that, in the investigator's judgment, makes the participant unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07353684, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07353684,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07353684